Breast cancer articles from across Nature Portfolio

A gravity-driven organoid perfusion (GDOP) chip is developed to establish uniform TNBC organoids for three-drug sensitivity testing via morphological and grayscale changes, and to generate brain organoids supporting further drug toxicity research.

Response to next-generation selective oestrogen receptor-α (ERα) antagonist/degraders (SERDs) in ER+ breast cancer patients can be promising, but responses in advanced, pre-treated disease are heterogenous. Here, using samples from breast cancer patients pre-and post-SERD treatment, the authors identify loss of luminal lineage and subsequent ERα independence as a driver of SERD resistance.

This Comment describes the clinical significance of the Mammography Screening with Artificial Intelligence (MASAI) trial, which is, to the best of our knowledge, the first randomized trial of artificial intelligence-supported mammography interpretation to examine interval cancer as an outcome. This trial used artificial intelligence to assign single-reading versus double-reading of mammograms and found that this approach does not increase interval cancers in the Swedish population.

An article in Technology in Cancer Research & Treatment reports the clinical evaluation of JULIETA, a portable, non-invasive, radiation-free device that uses bioimpedance spectroscopy and artificial intelligence to identify electrical tissue patterns associated with potentially malignant breast changes.